Corxel Pharmaceuticals Secures $287M to Advance Oral Obesity Drug and Cardiometabolic Pipeline

BERKELEY HEIGHTS, NJ – January 22, 2026 – Corxel Pharmaceuticals has successfully closed a $287 million Series D1 financing round, a major capital infusion intended to accelerate its charge into the highly competitive cardiometabolic disease space. The funding, led by a syndicate of prominent global healthcare investors, is primarily earmarked for the advancement of CX11, a promising oral small molecule GLP-1 receptor agonist aimed at the multi-billion-dollar obesity and diabetes markets.

The financing saw participation from new investors including SR One Capital Management, TCG Crossover (TCGX), and RA Capital Management, alongside continued support from existing backers like RTW Investments. This significant financial backing signals robust investor confidence in Corxel's strategy to challenge established players with more convenient, next-generation therapies.

“This investment is one of the most significant milestones for CORXEL since its founding as it not only fuels our effort to accelerate the global development of industry-leading therapies against cardiometabolic diseases but also propels the company to a new orbit of growth,” said Sandy Mou, Board Executive Director and Chief Executive Officer of CORXEL.

The Race for an Oral GLP-1 Heats Up

The development of CX11 comes at a pivotal moment. The global market for GLP-1 receptor agonists, valued at over $62 billion in 2025, is projected to soar to more than $254 billion by 2034. This explosive growth has been largely driven by highly effective, yet injectable, therapies from market titans Novo Nordisk and Eli Lilly.

However, the industry is on the cusp of a paradigm shift—an “oral revolution” driven by strong patient preference for pills over injections. Corxel's CX11 is an oral small molecule, a key distinction that could offer advantages in manufacturing and cost over the oral peptide-based drugs currently entering the market. The company is positioning CX11 to capture a significant share of the oral GLP-1 market, which itself is estimated to double from approximately $5 billion in 2025 to over $10.4 billion by 2033.

The competitive field is formidable. Novo Nordisk recently launched its oral version of Wegovy in the U.S. for weight management, marking a major milestone. Meanwhile, Eli Lilly’s own oral small molecule, orforglipron, is in late-stage trials and has already been labeled a potential “game changer” by analysts. Other companies, including Pfizer and Structure Therapeutics, are also advancing their own oral candidates.

Corxel’s confidence in CX11 is supported by early clinical signals. Data from a Phase 2 trial in China, conducted by its partner Vincentage, showed that a high dose of the drug led to a 9.7% reduction in body weight at 16 weeks. The new funding will now support an ongoing U.S. Phase 2 trial for obesity, a planned global Phase 2 trial for Type 2 Diabetes, and preparations for pivotal Phase 3 studies.

Investor Confidence Signals Strong Validation

The $287 million raised is more than just development capital; it is a powerful endorsement of Corxel’s science, leadership, and strategic vision. The syndicate of investors includes some of the most respected names in life science venture capital, such as RTW Investments, SR One, TCGX, RA Capital Management, and HBM Healthcare Investments. These firms are known for their deep scientific diligence and track record of backing successful biopharmaceutical ventures.

“We believe CORXEL’s clinical progress, disciplined execution, and seasoned leadership team position the company for important near-term catalysts and sustained long-term value creation,” stated Roderick Wong, Managing Partner at RTW Investments. “We are excited to support their journey toward becoming a leading biotech in the field of cardiometabolic disorders.”

This investment aligns with a broader surge of capital into the metabolic disease space. Private investment in obesity-focused biotech has grown tenfold between 2019 and 2025, reflecting the immense unmet medical need and commercial opportunity. The financing also strengthens Corxel's governance, with three new representatives from the investor group set to join the company's Board of Directors, ensuring strategic alignment and expert oversight as the company navigates its next phase of growth.

A Multi-Front Strategy for Cardiometabolic Disease

While the spotlight is on CX11, Corxel is building a diversified pipeline that tackles cardiometabolic health on multiple fronts. The company’s strategy acknowledges the interconnected nature of conditions like obesity, diabetes, hypertension, and stroke. The new funding will also be used to advance its other clinical-stage assets.

Among them is JX10, a novel agent for acute ischemic stroke that functions as both a thrombolytic and an anti-inflammatory. This dual mechanism could offer significant advantages over current treatments, which are often limited by narrow therapeutic windows. Another key program is JX09, a highly selective aldosterone synthase inhibitor for hypertension. By targeting a distinct point in the renin-angiotensin-aldosterone system, JX09 has the potential to become a new option for patients with difficult-to-treat or resistant hypertension.

This multi-asset strategy is characteristic of Corxel’s experienced management team. The company, which previously operated as JiXing Pharmaceuticals, has a demonstrated history of strategic agility, including the successful out-licensing of a cardiac drug candidate to Sanofi in 2024. This track record of savvy deal-making and pipeline management has clearly resonated with investors.

With a fortified balance sheet and a multi-pronged clinical strategy, Corxel is now positioned to execute on its ambitious vision of redefining treatment standards for some of the world's most prevalent and challenging diseases.